Related Experiment Video
Updated: Mar 12, 2026
02:28
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
990
New targets in psoriatic arthritis
1Rheumazentrum Ruhrgebiet, Herne, Ruhr University Bochum, Germany j.braun@rheumazentrum-ruhrgebiet.de.
Rheumatology (Oxford, England)
|November 19, 2016
Summary
New biologic and synthetic drugs offer improved treatment for psoriatic arthritis (PsA), a chronic inflammatory condition affecting skin and joints. These advancements, including IL-17 and IL-23 inhibitors, show promise for better patient outcomes.
Area of Science:
- Immunology
- Dermatology
- Rheumatology
Background:
- Psoriatic arthritis (PsA) is a complex, immune-mediated inflammatory disease impacting skin and joints.
- It presents heterogeneously with synovitis, enthesitis, dactylitis, and spondylitis, causing significant patient burden.
- Patient-reported outcomes are crucial for assessing PsA disease activity.
Purpose of the Study:
- To review recent advancements in psoriatic arthritis (PsA) treatment.
- To focus on novel biologic and synthetic agents.
- To highlight emerging therapeutic strategies for PsA management.
Main Methods:
- Review of current literature on psoriatic arthritis (PsA) therapeutics.
- Concentration on new biologic agents targeting IL-17 and IL-23 pathways.
- Examination of novel synthetic drugs including PDE4 and JAK inhibitors.
Main Results:
- Biologic agents such as IL-17 inhibitors (secukinumab) and anti-IL-23 agents (ustekinumab) are key developments.
- Novel synthetic drugs include apremilast (PDE4 inhibitor) and tofacitinib (JAK inhibitor).
- Some new agents demonstrate potentially superior efficacy for skin manifestations compared to joint involvement in PsA.
Conclusions:
- Emerging biologic and synthetic therapies offer new avenues for psoriatic arthritis (PsA) management.
- Targeted therapies like IL-17, IL-23, PDE4, and JAK inhibitors represent significant progress.
- The potential for differential efficacy on skin versus joints warrants further investigation in PsA treatment.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
01:26Targets for Drug Action: Overview
10.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.9K
01:29Pharmacogenomics: Identification of New Drug Targets
59
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
59
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
688
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
688
01:29Inflammatory Bowel Disease IV: Pharmacological Management
883
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
883
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
573
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
573